Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Marie-Sophie Dheur, Hélène A. Poirel, Geneviève Ameye, Gaëlle Tilman, Pascale Saussoy, Jean-Philippe Defour, Alessandra Camboni, Eric Van Den Neste, Pierre G. Coulie & Nicolas van Baren. (2019) Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies. Leukemia & Lymphoma 60:4, pages 1043-1052.
Read now
Read now
Darius Juskevicius, Anne Müller, Hind Hashwah, Pontus Lundberg, Alexandar Tzankov & Thomas Menter. (2018) Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines. Leukemia & Lymphoma 59:7, pages 1710-1716.
Read now
Read now
Articles from other publishers (20)
Stefan Nagel, Claudia Pommerenke, Corinna Meyer, Maren Kaufmann & Roderick A. F. MacLeod. (2023) Chromosomal Aberration t(14;17)(q32;q21) Simultaneously Activates HOXB5 and miR10a in Triple-Hit B-Cell Lymphoma. Biomedicines 11:6, pages 1758.
Crossref
Crossref
Jessie S. Kroonen, Ilona J. de Graaf, Sumit Kumar, Dennis F. G. Remst, Anne K. Wouters, Mirjam H. M. Heemskerk & Alfred C. O. Vertegaal. (2023) Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies. Leukemia 37:4, pages 864-876.
Crossref
Crossref
Jibin Zhang, Tingting Wang, Kunal Shetty, Serhan Alkan, Senlin Xu, Qiang Gong, Xuxiang Liu, Yuping Li, Zunsong Hu, Wendong Huang, Hans-Guido Wendel, Alex F. Herrera, Raju K. Pillai, Joo Y. Song & Wing C. Chan. (2022) Genetic characterization and drug sensitivity study of newly derived HGBL double/triple-hit lymphoma cell lines. Blood Advances 6:17, pages 5067-5071.
Crossref
Crossref
Stefan Nagel. (2021) The Role of NKL Homeobox Genes in T-Cell Malignancies. Biomedicines 9:11, pages 1676.
Crossref
Crossref
Stefan Nagel. (2021) NKL-Code in Normal and Aberrant Hematopoiesis. Cancers 13:8, pages 1961.
Crossref
Crossref
Hans G. Drexler & Hilmar Quentmeier. (2020) The LL-100 Cell Lines Panel: Tool for Molecular Leukemia–Lymphoma Research. International Journal of Molecular Sciences 21:16, pages 5800.
Crossref
Crossref
Min Chen, Guoxiong Jiang, Yichen Liu, Dongya Li, Tiantian Li, Jie Peng, Qian Jiang, Haiyan You, Rong Ba, Jinlan Pan, Mei Li, Weiguo Long, Jinsong Yan, Yan Zhu, Yun Wang, Xiaodong Xi, Jianhua Mao & Xiaofeng Shi. (2020) Establishment and characterization of a novel ‘double‐hit’ follicular lymphoma cell line, FL‐SJC. Journal of Cellular and Molecular Medicine 24:14, pages 7928-7938.
Crossref
Crossref
Hafidha Bentayeb, Marine Aitamer, Barbara Petit, Lydie Dubanet, Sabria Elderwish, Laurent Désaubry, Armand de Gramont, Eric Raymond, Agnès Olivrie, Julie Abraham, Marie-Odile Jauberteau & Danielle Troutaud. (2019) Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Crossref
Stefan Nagel & Hans G. Drexler. (2019) Deregulated NKL Homeobox Genes in B-Cell Lymphoma. Cancers 11:12, pages 1874.
Crossref
Crossref
Jennifer K. Lue, Sathyen A. Prabhu, Yuxuan Liu, Yulissa Gonzalez, Akanksha Verma, Prabhjot S. Mundi, Nebiyu Abshiru, Jeannie M. Camarillo, Swasti Mehta, Emily I. Chen, Changhong Qiao, Renu Nandakumar, Serge Cremers, Neil L. Kelleher, Olivier Elemento & Jennifer E. Amengual. (2019) Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas. Clinical Cancer Research 25:17, pages 5271-5283.
Crossref
Crossref
Chidimma Agatha Akpa, Karsten Kleo, Dido Lenze, Elisabeth Oker, Lora Dimitrova & Michael Hummel. (2019) DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations. PLOS ONE 14:8, pages e0220681.
Crossref
Crossref
Mirabelli, Coppola & Salvatore. (2019) Cancer Cell Lines Are Useful Model Systems for Medical Research. Cancers 11:8, pages 1098.
Crossref
Crossref
Stefan Nagel, Cord C. Uphoff, Wilhelm G. Dirks, Claudia Pommerenke, Corinna Meyer & Hans G. Drexler. (2019) Epstein-Barr virus (EBV) activates NKL homeobox gene HLX in DLBCL. PLOS ONE 14:5, pages e0216898.
Crossref
Crossref
Shrikant S. Kolan, Tommy Lidström, Tomás Mediavilla, Andy Dernstedt, Sofie Degerman, Magnus Hultdin, Karl Björk, Daniel Marcellino & Mattias N. E. Forsell. (2019) Growth-inhibition of cell lines derived from B cell lymphomas through antagonism of serotonin receptor signaling. Scientific Reports 9:1.
Crossref
Crossref
Hiroaki Kikuchi, Tomonori Higuchi, Yumiko Hashida, Ayuko Taniguchi, Mikio Kamioka, Takahiro Taguchi, Akihito Yokoyama, Ichiro Murakami, Mikiya Fujieda & Masanori Daibata. (2018)
Generation and characteristics of a novel “double-hit” high grade B-cell lymphoma cell line DH-My6 with
MYC
/
IGH
and
BCL6
/
IGH
gene arrangements and potential molecular targeted therapies
. Oncotarget 9:71, pages 33482-33499.
Crossref
Crossref
Hans G. Drexler, Claudia Pommerenke, Sonja Eberth & Stefan Nagel. (2018) Hodgkin lymphoma cell lines: to separate the wheat from the chaff. Biological Chemistry 399:6, pages 511-523.
Crossref
Crossref
A. Esteve-Arenys, J. G. Valero, A. Chamorro-Jorganes, D. Gonzalez, V. Rodriguez, I. Dlouhy, I. Salaverria, E. Campo, D. Colomer, A. Martinez, G. Rymkiewicz, P. Pérez-Galán, A. Lopez-Guillermo & G. Roué. (2018) The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. Oncogene 37:14, pages 1830-1844.
Crossref
Crossref
Micol Ravà, Aleco D’Andrea, Paola NicoliIlaria GrittiGiulio DonatiMirko DoniMarco Giorgio, Daniela OliveroBruno Amati. (2018)
Therapeutic synergy between tigecycline and venetoclax in a preclinical model of
MYC
/
BCL2
double-hit B cell lymphoma
. Science Translational Medicine 10:426.
Crossref
Crossref
Maureen C. Ryan, Maria Corinna Palanca-Wessels, Brian Schimpf, Kristine A. Gordon, Heather Kostner, Brad Meyer, Changpu Yu, Heather A. Van Epps & Dennis Benjamin. (2017) Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies. Blood 130:18, pages 2018-2026.
Crossref
Crossref
Hilmar Quentmeier, Hans G. Drexler, Vivien Hauer, Roderick A. F. MacLeod, Claudia Pommerenke, Cord C. Uphoff, Margarete Zaborski, Mattias Berglund, Gunilla Enblad & Rose-Marie Amini. (2016) Diffuse Large B Cell Lymphoma Cell Line U-2946: Model for MCL1 Inhibitor Testing. PLOS ONE 11:12, pages e0167599.
Crossref
Crossref